Contact
searchSearch
HMP Global
Login

Major Depressive Disorder Topic Center

A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results published in JAMA...
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results published in JAMA...
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
A man with depression holds his head in his hands
News
Lumateperone Tops Efficacy in Adjunctive Treatment for MDD, Review Finds
05/12/2026
Brionna Mendoza
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and...
05/12/2026
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
News
Semaglutide May Improve Motivation in MDD, Small Trial Finds
05/04/2026
Brionna Mendoza
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial...
05/04/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
PGx Testing in MDD
04/27/2026
Maria Mantas
Can you recall how the use of pharmacogenomic testing impacted treatment outcomes in major depressive disorder (MDD)?
Can you recall how the use of pharmacogenomic testing impacted treatment outcomes in major depressive disorder (MDD)?
Can you recall how the use of...
04/27/2026
Psych Congress Network
A doctor sits at a table holding a pill bottle in one hand while filling out paperwork
News
Algorithm-Guided Treatment Improves Outcomes in Major Depressive Disorder
04/14/2026
Brionna Mendoza
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in...
04/14/2026
Psych Congress Network
a man with depression looks out a window major depressive disorder
Research Summary
Psilocybin Produces Mixed Outcomes in Phase 2b MDD Study
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network
a white jigsaw puzzle of a brain against an orange background with one puzzle piece missing
News
AMPA Receptor Modulation Shows Promise in Major Depressive Disorder Treatment
03/24/2026
Brionna Mendoza
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP...
03/24/2026
Psych Congress Network
a person holds a glass of water and pills
News
Antidepressant Use Patterns May Help Personalize MDD Treatment
03/16/2026
Brionna Mendoza
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in...
03/16/2026
Psych Congress Network
orange pill bottle antidepressant depression major depressive disorder MDD
News
Decision Tool Reduces Antidepressant Dropout in Major Depressive Disorder
03/06/2026
Brionna Mendoza
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support...
03/06/2026
Psych Congress Network
psilocybin-containing mushrooms in a beaker
Research Summary
Synthetic Psilocybin Meets Primary Endpoint in Phase 3 Treatment-Resistant Depression Trial
02/19/2026
Maria Mantas
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin...
02/19/2026
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet.
Quiz
Intranasal Esketamine Dosage for Adult MDD
02/04/2026
Brionna Mendoza
Test your prescribing and administration knowledge with this quiz!
Test your prescribing and administration knowledge with this quiz!
Test your prescribing and...
02/04/2026
Psych Congress Network

News

A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results published in JAMA...
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results published in JAMA...
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
A man with depression holds his head in his hands
News
Lumateperone Tops Efficacy in Adjunctive Treatment for MDD, Review Finds
05/12/2026
Brionna Mendoza
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and...
05/12/2026
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
News
Semaglutide May Improve Motivation in MDD, Small Trial Finds
05/04/2026
Brionna Mendoza
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial...
05/04/2026
Psych Congress Network
A doctor sits at a table holding a pill bottle in one hand while filling out paperwork
News
Algorithm-Guided Treatment Improves Outcomes in Major Depressive Disorder
04/14/2026
Brionna Mendoza
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in...
04/14/2026
Psych Congress Network
a man with depression looks out a window major depressive disorder
Research Summary
Psilocybin Produces Mixed Outcomes in Phase 2b MDD Study
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network
a white jigsaw puzzle of a brain against an orange background with one puzzle piece missing
News
AMPA Receptor Modulation Shows Promise in Major Depressive Disorder Treatment
03/24/2026
Brionna Mendoza
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP...
03/24/2026
Psych Congress Network
a person holds a glass of water and pills
News
Antidepressant Use Patterns May Help Personalize MDD Treatment
03/16/2026
Brionna Mendoza
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in...
03/16/2026
Psych Congress Network
orange pill bottle antidepressant depression major depressive disorder MDD
News
Decision Tool Reduces Antidepressant Dropout in Major Depressive Disorder
03/06/2026
Brionna Mendoza
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support...
03/06/2026
Psych Congress Network
psilocybin-containing mushrooms in a beaker
Research Summary
Synthetic Psilocybin Meets Primary Endpoint in Phase 3 Treatment-Resistant Depression Trial
02/19/2026
Maria Mantas
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin...
02/19/2026
Psych Congress Network
A man looks out a window
News
Adjunctive Vagus Nerve Stimulation Shows Durable Benefit in Treatment-Resistant Depression
01/20/2026
Maria Mantas
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study...
01/20/2026
Psych Congress Network
A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results published in JAMA...
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results published in JAMA...
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
injection for schizophrenia treatment
News
Once-Monthly Aripiprazole Demonstrates Favorable Benefit–Risk Profile in Schizophrenia Treatment
05/14/2026
Maria Mantas
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg...
05/14/2026
Psych Congress Network
A man with depression holds his head in his hands
News
Lumateperone Tops Efficacy in Adjunctive Treatment for MDD, Review Finds
05/12/2026
Brionna Mendoza
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
News
The Link Between Ultra-Processed Foods and ADHD
05/12/2026
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a...
05/12/2026
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
News
Semaglutide May Improve Motivation in MDD, Small Trial Finds
05/04/2026
Brionna Mendoza
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial...
05/04/2026
Psych Congress Network
A patient receives psychedelic-assisted therapy
News
Presidential Executive Order Seeks to Expand Psychedelic Access for Tough-To-Treat Mental Illnesses
04/29/2026
Brionna Mendoza
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed...
04/29/2026
Psych Congress Network
a female soldier stands in front of a row of American flags
News
TMS Improves Residential Therapy Outcomes in Combat-Related PTSD
04/22/2026
Maria Mantas
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
Active navigated transcranial...
04/22/2026
Psych Congress Network
A doctor sits at a table holding a pill bottle in one hand while filling out paperwork
News
Algorithm-Guided Treatment Improves Outcomes in Major Depressive Disorder
04/14/2026
Brionna Mendoza
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in...
04/14/2026
Psych Congress Network
a person attempts to pick up a glass of water
News
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients
04/14/2026
Maria Mantas
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported...
04/14/2026
Psych Congress Network
A boy's hand holding a pill that says ADHD
News
Open-Label Extension Trial Supports Long-Term Use of Viloxazine ER in Children and Adolescents
04/13/2026
A phase 3 open-label extension trial found viloxazine ER to be safe and effective for the long-term treatment of pediatric ADHD.
A phase 3 open-label extension trial found viloxazine ER to be safe and effective for the long-term treatment of pediatric ADHD.
A phase 3 open-label extension...
04/13/2026
Psych Congress Network

Quizzes

an illustrated laptop screen displaying a quiz
Quiz
PGx Testing in MDD
04/27/2026
Maria Mantas
Can you recall how the use of pharmacogenomic testing impacted treatment outcomes in major depressive disorder (MDD)?
Can you recall how the use of pharmacogenomic testing impacted treatment outcomes in major depressive disorder (MDD)?
Can you recall how the use of...
04/27/2026
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet.
Quiz
Intranasal Esketamine Dosage for Adult MDD
02/04/2026
Brionna Mendoza
Test your prescribing and administration knowledge with this quiz!
Test your prescribing and administration knowledge with this quiz!
Test your prescribing and...
02/04/2026
Psych Congress Network
quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network
quiz
Quiz
Oral Fluoxetine Dosing for Adults With Major Depressive Disorder
06/12/2025
Meagan Thistle
Test your psychopharmacology knowledge: What is the recommended starting dose of oral fluoxetine for MDD in adults? The maximum dose should not exceed how many mg per day?
Test your psychopharmacology knowledge: What is the recommended starting dose of oral fluoxetine for MDD in adults? The maximum dose should not exceed how many mg per day?
Test your psychopharmacology...
06/12/2025
Psych Congress Network
stacked blocks that spell out the word "quiz"
Quiz
Initial Treatment Approach for Adults in Acute Phase MDD in Ambulatory Care
04/17/2025
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial...
04/17/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
DSM-5
Quiz
How does the DSM-5 define 'remission' in MDD?
12/13/2024
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of...
12/13/2024
Psych Congress Network
DSM-5
Quiz
How does the chronicity of depressive symptoms affect MDD treatment and outcomes?
12/11/2024
Meagan Thistle
12/11/2024
Psych Congress Network
quiz
Quiz
What is esketamine indicated to treat?
12/02/2024
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive...
12/02/2024
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
Quiz
Test Your Knowledge: The Link Between Ultra-Processed Foods and ADHD
05/12/2026
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the...
05/12/2026
Psych Congress Network
Nishi Bhopal, MD
Quiz
First Steps in Identifying Excessive Daytime Sleepiness
05/06/2026
Maria Mantas
What is the recommended first step to confirm whether a patient is experiencing excessive daytime sleepiness? Take this quick quiz to test your knowledge!
What is the recommended first step to confirm whether a patient is experiencing excessive daytime sleepiness? Take this quick quiz to test your knowledge!
What is the recommended first...
05/06/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Mortality Risk in Bipolar II Disorder
04/30/2026
Maria Mantas
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between...
04/30/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
PGx Testing in MDD
04/27/2026
Maria Mantas
Can you recall how the use of pharmacogenomic testing impacted treatment outcomes in major depressive disorder (MDD)?
Can you recall how the use of pharmacogenomic testing impacted treatment outcomes in major depressive disorder (MDD)?
Can you recall how the use of...
04/27/2026
Psych Congress Network
a girl playing a game on a tablet while lying on her stomach
Quiz
Test Your Knowledge—Digital Therapeutics: A Different Treatment Modality for ADHD
04/23/2026
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx...
04/23/2026
Psych Congress Network
A boy's hand holding a pill that says ADHD
Quiz
Long-Term Effects of Viloxazine ER in Treatment of Pediatric ADHD
04/23/2026
Ready to apply the data? Test your knowledge of viloxazine ER for the long-term treatment of pediatric ADHD.
Ready to apply the data? Test your knowledge of viloxazine ER for the long-term treatment of pediatric ADHD.
Ready to apply the data? Test...
04/23/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Quiz
Why should anticholinergics be avoided in TD?
04/17/2026
Maria Mantas
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why...
04/17/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Quiz
Why should anticholinergics be avoided in TD?
04/17/2026
Maria Mantas
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why...
04/17/2026
Psych Congress Network
Edward Kaftarian, MD
Quiz
Legal Considerations in Cross-State Telepsychiatry
03/23/2026
Maria Mantas
Test your knowledge with this faculty insights quiz!
Test your knowledge with this faculty insights quiz!
Test your knowledge with this...
03/23/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use